Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient(®) in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06)

SIMPLE SUMMARY: There are very few systemic treatment options for patients with advanced angiosarcomas. We therefore examined whether combined treatment with paclitaxel and pazopanib was active and well tolerated. However, we did not meet a preplanned interim target of 6/14 patients without progress...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Pink, Daniel, Andreou, Dimosthenis, Bauer, Sebastian, Brodowicz, Thomas, Kasper, Bernd, Reichardt, Peter, Richter, Stephan, Lindner, Lars H., Szkandera, Joanna, Grünwald, Viktor, Kebenko, Maxim, Kirchner, Marietta, Hohenberger, Peter
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8000466/
https://ncbi.nlm.nih.gov/pubmed/33799576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13061223
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars